The Uppsala team presented at the Vårmöte klinisk kemi

The Uppsala team presented at the Vårmöte klinisk kemi

The Uppsala team presented at the Vårmöte klinisk kemi, 5-7 April in Tylösand, Sweden. Here Torbjörn is presenting our MS based assays for analysing PEth (a marker for alcohol consumption measured in blood) and cortisol/cortison measurements in urine. The methods have been in clinical use for more than a year now at Akademiska sjukhuset. Kim is also presenting an ultrasensitive method for detecting trace levels of levonorgestrel. The method is in use for detecting if lost contraceptive coils are present or not in the body, and the method can also be used for environmental monitoring in e.g. aquatic species.

Drug discovery and development

Drug discovery and development

In collaboration with the SciLifeLab Drug Discovery and Development (DDD) platform we are running a pilot project aimed at establishing standardized protocols for metabolic and proteomic profiling of drug candidate effects in different in vitro cell based model systems.

Clinical Metabolomics & proteomics

Clinical Metabolomics & proteomics

We have developed and implemented mass spectrometry based methods for metabolomics and proteomics, including targeted and untargeted analyses of hormones, lipids and small signaling molecules in human CSF and in vitro cell cultures. We are currently involved in three large efforts; characterization and prediction of in vitro cell toxicity of exogenous substances (such as environmental contaminants and cancer drugs), better diagnostic markers for chronic pain states and early detection of Alzheimer’s disease. We are also part of the newly launched EU Horizon 2020 project “PhenoMeNal” with focus on implementing clinical metablomics into the clinic.

Torbjörn Åkerfeldt, MD

Torbjörn Åkerfeldt, MD

Medical management responsible physician
Acting Section Head, Chief

E-mail: [email protected]
Phone: +46 18 6114272
Website: http://www.akademiska.se/sv/Verksamheter/Akademiska-laboratoriet/Klinisk-kemi-och-farmakologi/

Stephanie Herman

Stephanie Herman

PhD student

With a background in bioengineering, bioinformatics and molecular biotechnology, Stephanie Herman has recently joined CARAMBA as a PhD student. Her shared focus and interests’ lies in the challenges provided by the data complexity and size of large-scale metabolomic studies and analyses of clinical metabolic data from patient diagnosed with various neurological diseases. Stephanie is part of work package 5 in the EU Horizon 2020 project PhenoMeNal, where they intend to develop a cloud-based e-infrastructure that enables scientists and health care providers to process and analyse medical metabolomics data for improved health care. Previously, Stephanie was part of the Uppsala iGEM team 2013 and project leader in the Uppsala iGEM team 2014, where she competed in the worldwide competition in Synthetic Biology hosted by Massachusetts Institute of Technology (MIT).

E-mail: [email protected]
Phone: +46 18 6115959
Website: http://katalog.uu.se/profile/?id=N15-2239_1

Neuropeptidomics

We have developed methods for analyses of endogenously expressed neuropeptides in vivo and in vitro. These efforts include identifying novel targets for treatment of chronic pain states in humans and better understanding of neurological effects caused by environmental contaminants.